200 related articles for article (PubMed ID: 2714071)
21. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
23. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
24. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
[TBL] [Abstract][Full Text] [Related]
25. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
Canawati HN
Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
[TBL] [Abstract][Full Text] [Related]
26. Antibiotic- and method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates.
Aldridge KE; Sanders CV
J Clin Microbiol; 1987 Dec; 25(12):2317-21. PubMed ID: 3480894
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antibacterial interaction of cefotaxime and desacetylcefotaxime.
Molinari G; Saverino D; Paglia P; Debbia EA; Schito GC
J Chemother; 1991 Feb; 3(1):6-12. PubMed ID: 2019866
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
[TBL] [Abstract][Full Text] [Related]
29. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
[TBL] [Abstract][Full Text] [Related]
30. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility to five antimicrobial agents of strains of the Bacteroides fragilis group isolated in Brazil.
De Almeida AE; De Uzeda M
Antimicrob Agents Chemother; 1987 Apr; 31(4):617-8. PubMed ID: 3649203
[TBL] [Abstract][Full Text] [Related]
32. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
Aldridge KE; Sanders CV; Marier RL
Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):47S-53S. PubMed ID: 6086218
[TBL] [Abstract][Full Text] [Related]
33. [Activity of seven antimicrobial agents against "Bacteroides fragilis" (author's transl)].
Tytgat F
Ann Microbiol (Paris); 1980; 131(1):39-44. PubMed ID: 6899739
[TBL] [Abstract][Full Text] [Related]
34. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
[TBL] [Abstract][Full Text] [Related]
35. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
Betriu C; Cabronero C; Gomez M; Picazo JJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
Appleman MD; Heseltine PN; Cherubin CE
Rev Infect Dis; 1991; 13(1):12-8. PubMed ID: 2017610
[TBL] [Abstract][Full Text] [Related]
37. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.
Lee K; Chong Y; Jeong SH; Xu XS; Kwon OH
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S73-7. PubMed ID: 8953110
[TBL] [Abstract][Full Text] [Related]
38. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
Aldridge KE; Weeks LS; Stratton CW; Sanders CV
Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
[TBL] [Abstract][Full Text] [Related]
39. Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.
Marone P; Navarra A; Monzillo V; Traverso A
Drugs Exp Clin Res; 1990; 16(12):629-33. PubMed ID: 2130005
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.
Fuchs PC; Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(1):81-5. PubMed ID: 2714075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
